Erosive Pustular Dermatosis and Amivantamab for Lung Cancer: A Case Report.

IF 0.9 Q4 DERMATOLOGY
Case Reports in Dermatology Pub Date : 2025-06-13 eCollection Date: 2025-01-01 DOI:10.1159/000546616
Yseult Senterre, Amandine Bouillenne, Murielle Sabatiello, Anne-Sophie Demoulin, Arjen F Nikkels
{"title":"Erosive Pustular Dermatosis and Amivantamab for Lung Cancer: A Case Report.","authors":"Yseult Senterre, Amandine Bouillenne, Murielle Sabatiello, Anne-Sophie Demoulin, Arjen F Nikkels","doi":"10.1159/000546616","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Amivantamab is a monoclonal antibody against EGFR and MET receptors, indications for certain types of non-small cell lung cancer. Due to its mechanisms, cutaneous adverse effects are frequent and numerous.</p><p><strong>Case presentation: </strong>A 67-year-old woman with metastatic adenosquamous carcinoma, stage T3N2M1c, was treated with amivantamab after the first-line chemotherapy failed. Despite prophylactic oral tetracyclines, she developed severe erosive pustular dermatosis (EPD) affecting more than 50% of her scalp, forcing to cut short her hair to provide adequate local care.</p><p><strong>Conclusion: </strong>EPD is an exceptional and severe adverse event of amivantamab, requiring oral steroids, tetracyclines and appropriate local care with antibiotic creams. Clinicians should be aware of this complication as early therapeutic intervention is mandatory to avoid deleterious consequences and spontaneous recurrences.</p>","PeriodicalId":9619,"journal":{"name":"Case Reports in Dermatology","volume":"17 1","pages":"263-267"},"PeriodicalIF":0.9000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240574/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Dermatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000546616","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Amivantamab is a monoclonal antibody against EGFR and MET receptors, indications for certain types of non-small cell lung cancer. Due to its mechanisms, cutaneous adverse effects are frequent and numerous.

Case presentation: A 67-year-old woman with metastatic adenosquamous carcinoma, stage T3N2M1c, was treated with amivantamab after the first-line chemotherapy failed. Despite prophylactic oral tetracyclines, she developed severe erosive pustular dermatosis (EPD) affecting more than 50% of her scalp, forcing to cut short her hair to provide adequate local care.

Conclusion: EPD is an exceptional and severe adverse event of amivantamab, requiring oral steroids, tetracyclines and appropriate local care with antibiotic creams. Clinicians should be aware of this complication as early therapeutic intervention is mandatory to avoid deleterious consequences and spontaneous recurrences.

糜烂性脓疱性皮肤病与阿米万他单抗治疗肺癌1例报告。
Amivantamab是一种针对EGFR和MET受体的单克隆抗体,适用于某些类型的非小细胞肺癌。由于其机制,皮肤的不良反应是频繁和众多的。病例介绍:一名67岁的女性转移性腺鳞癌,T3N2M1c期,在一线化疗失败后接受阿米万他单抗治疗。尽管预防性口服四环素,她还是患上了严重的糜烂性脓疱性皮肤病(EPD),影响了50%以上的头皮,迫使她剪短头发以提供适当的局部护理。结论:EPD是阿米万他单的一种特殊且严重的不良事件,需要口服类固醇、四环素和适当的局部护理,使用抗生素乳膏。临床医生应该意识到这种并发症,因为早期治疗干预是强制性的,以避免有害的后果和自发复发。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.60
自引率
0.00%
发文量
57
审稿时长
9 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信